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Abstract 
Background: Electrochemotherapy (ECT) is an effective local treatment for 
cutaneous metastasis. Treatment involves the administration of chemotherapeutic 
drugs followed by delivery of electrical pulses to the tumour. The aim of this study 
was to investigate the effectiveness of ECT in cutaneous metastases of melanoma 
and to identify factors which affect (beneficially or adversely) the outcome. 
 
Methods: 13 cancer centres in the International Network for Sharing Practices on 
Electrochemotherapy (INSPECT) consecutively and prospectively uploaded data to 
a common database. ECT consisted of intratumoural or intravenous injection of 
bleomycin, followed by application of electric pulses under local or general 
anaesthesia.  
 
Results: 151 patients with metastatic melanoma were identified from the database, 
114 of which had follow-up data of 60 days or more. 80 of these patients (73 %) 
experienced an overall response (complete response + partial response = OR). 394 
lesions were treated, of which 306 (77 %) revealed an OR, 229 a complete response 
(58 %). In multivariate analysis, factors positively associated with overall response 
were coverage of deep margins, absence of visceral metastases, presence of 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
lymphoedema, treatment of non-irradiated areas were factors significantly 
influencing treatment efficacy. Factors significant associated to a complete response 
to ECT treatment were: coverage of deep margins, previous irradiation of treated 
area, and tumour size (<3 cm). One-year overall survival in this cohort of patients 
was 67% (C.I. 95%: 57%-77%), whilst melanoma specific survival was 74% (C.I. 
95%: 64%-84%). No serious adverse events were reported, and the treatment was in 
general very well tolerated. 
 
Conclusion: ECT is a highly effective local treatment for melanoma metastases in 
the skin, with no severe adverse effects. In the presence of certain clinical factors, 
ECT may be considered for local tumour control as an alternative to established local 
treatments, or as an adjunct to systemic treatments. .  
 
Keywords: Electrochemotherapy, malignant melanoma, palliative care, bleomycin. 
 
Bulleted summary 
 
What's already known about this topic? 
Electrochemotherapy (ECT) is an effective local treatment for cutaneous metastasis. 
Treatment efficacy is correlated to tumour size. 
 
What does this study add? 
With multivariate analysis, several new factors associated with a favourable 
response to treatment have been identified: coverage of deep tumour margin, 
presence of lymphoedema, treatment of non-irradiated areas, and absence of 
visceral metastases. 
 
Introduction 
 
Therapy and management of metastatic melanoma is challenging. Melanoma 
accounts for about 18% of the total cases of cutaneous metastases 1,2. Patients with 
metastatic disease may suffer reduced quality of life because of pain, discharge, 
bleeding, and malodour of the tumours. In this advanced stage of disease, a 
multimodal palliative treatment, focusing on alleviating symptoms for the patients, is 
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required. Established therapeutic options include surgery, immunotherapy, systemic 
chemotherapy, isolated limb perfusion, radiotherapy, laser ablation and 
radiofrequency ablation, depending on the location of metastases and the condition 
of the patient 3,4. 
 
Electrochemotherapy (ECT) is a well-established treatment option for cutaneous and 
subcutaneous metastases, including melanoma 5. Originally, it was used for the 
treatment of metastatic head and neck cancer 6 and has since been established in 
the treatment of tumours of different histological types. Moreover, it has a favourable 
risk-to-benefit profile due to its simplicity, cost-effectiveness, safety and limited 
toxicity 7. 
 
Electroporation is a physical delivery system to enhance the penetration of different 
types of molecules, e.g. drugs 6. The use of short electrical local pulses via an 
electrode leads to destabilisation of the cell membrane and transiently increases the 
permeability of the tumour cell membrane, thus enabling diffusion of the agents. This 
potentiates the cytotoxicity of the non-permeant or poorly-permeant anticancer drug 
6,8
. The secondary actions of ECT include a reduction of tumour blood flow and a 
localised vascular disruption resulting in increased effectiveness of the drug 9-11. 
Bleomycin and cisplatin have been identified as the most suitable and effective drugs 
for ECT and can be used intratumourally or intravenously 12. The cytotoxic effect of 
Bleomycin is potentiated approximately 8000 times, and that of Cisplatin 80 times 13. 
 
Several studies have investigated the effectiveness of ECT 2,13-30. A study on the 
efficacy and safety of ECT published in 2006 by Mir et al. established the European 
standard operating procedures (ESOPE) 23. Kis et al. compared their outcomes of 
ECT in patients with melanoma with the results of the ESOPE study 13. A recent 
systematic review has compared different studies on therapies for cutaneous 
tumours regarding overall effectiveness 31.  
 
ECT has been recognized by a number of national health services, including the 
National Institute for Health and Care Excellence (NICE) as an integral part of the 
multidisciplinary treatment options for patients with skin metastases of non-skin 
origin and melanoma 5. 
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ECT has been reported to be highly effective in the treatment of cutaneous and 
subcutaneous metastases. Objective response rates range from 75-99% 8,13,23,31. 
The high response rates found consistently across studies reflect a dramatic 
increase of the cytotoxic effect of the cytostatic drugs, such as bleomycin, when 
access into the cell cytosol is facilitated by permeabilization of the plasma 
membrane. In order for the therapy to work efficiently it is important that sufficient 
drug dose is present, and that the tumour volume is covered by the electric pulses 
21,23
. 
 
The aim of this study was to   review the effectiveness of ECT in cutaneous 
metastases of melanoma and to identify factors which affect (beneficially or 
adversely) the outcome. Local progression free and overall survival were further 
aims of the study. The results may be used prospectively to further improve the 
effectiveness of ECT in metastatic melanoma. This study focussed on the response 
of ECT to local disease in the skin, and did not compare response rates with other 
treatment modalities for metastatic disease. 
 
Methods 
Patients 
Patients were treated consecutively at 13 institutions in the INSPECT network 
(Bristol, Copenhagen, London, Manchester, Middlesbrough, Munich, Padova, Pavia, 
Prescot Merceyside, Rome, Turin, Warsaw, Wels). Patients were consented, then 
data entered onto the database and subsequently updated over time. All centres 
uploaded data prospectively. No patient subsequently asked for their data to be 
removed from the database. Accrual time was from July 2007 to September 2014. 
Approval from ethics committee, and data protection authority was sought by each 
institution. Clinical information retrieved from the database included: demographics; 
type of tumour; number of treated lesions, site and size of the largest lesion, 
previous irradiation, duration of follow-up, and possible retreatment with ECT at 
subsequent time point. Patients treated had histologically malignant melanoma with 
measurable cutaneous metastases, or mucosal lesions, suitable for application of 
electric pulses. Patients had been offered standard treatment options, were ≥18 
years old, had Eastern Cooperative Oncology Group (ECOG) performance status 
≤2, a life expectancy of at least three months, and, if fertile were using adequate 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
contraception. Patients were not treated if they previously had allergic reactions to 
bleomycin or to any of the components required for anaesthesia, if the cumulative 
dose of 250 mg bleomycin/m2 (400.000 IU bleomycin/m2) had previously been 
exceeded, had chronic renal dysfunction (serum creatinine >150 μmol/l) or acute 
lung infection. Metastases were targeted for ECT regardless of pigmentation. 
 
Procedure 
ECT was performed according to the ESOPE Standard Operating Procedures 23. 
Briefly, bleomycin was administrated either intratumourally (i.t.) using 1000 IU/ml or 
intravenously (i.v) using 15.000 IU/m2, intratumoural or intravenous dosage was 
chosen depending on the number of cutaneous metastases to be treated and size of 
metastases. Depending on clinician's choice, one of the following electrodes was 
used: 1) Type I electrodes: two plates with a 6 mm gap between the plates; 2) Type II 
electrodes: two parallel rows of needles with 4 mm between rows; 3) Type III 
electrodes: a hexagonal array with 7.9 mm between the needles. Electric pulses 
(eight pulses of 100 μs duration) were delivered using a square wave electroporator 
(IGEA, Carpi, Italy). After ECT, the treated metastases were covered with standard 
dressings where necessary. 
Coverage of deep and lateral margins were not pre-specified, but was at the treating 
physician’s discretion, and the database offered a possibility for the physician to 
indicate whether these respective margins were completely covered/ treated or not. 
Targeting deep margin was assessed either clinically by palpating subcutaneous 
infiltration or fixation to the depth, or by using ultrasound. 
 
Response evaluation  
Locoregional tumour response was evaluated according to the Response Evaluation 
Criteria in Solid Tumours (RECIST version 1.0), modified to only include response of 
the treated cutaneous metastases. Complete response (CR) was defined as 
disappearance of the target lesion; partial response (PR) with at least 30% decrease 
in the diameter of the target lesion. Progressive disease (PD) was defined as at least 
20% increase in the diameter of the target lesion and stable disease (SD) with 
neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for PD. A 
maximum of seven cutaneous metastases per patient (including the largest tumour) 
were registered as target lesions, as in previous studies 2,21. The longest diameter of 
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the tumours was measured and recorded and photographs taken at the time of 
treatment, and at subsequent follow-up visits. 
 
 
Pre-operative evaluation 
Selection of the target nodule was performed according to the RECIST criteria 
(version 1.1). Pain intensity was evaluated using the Numeric Rating Scale (NRS) for 
pain. NRS is a unidimensional 11-point numeric scale between ‘0’ as ‘no pain’ and 
‘10’ as ‘worst pain’. We used a previously published cut-off on NRS score: 0-2 mild 
pain, 3-4 moderate pain, and 5-10 severe pain. Pain medication was registered as 
‘none’, ‘sometimes’, ‘controlled by non-opioids’, ‘controlled by opioids’, ‘uncontrolled’, 
or ‘unknown’. Evaluation of pain and pain medication was repeated at follow-up visit 
32
. 
 
Statistics 
Continuous variables were described by median value and interquartile range, 
categorical variables by absolute number and percentage. Analysis of response for 
different lesions’ sizes have been reported on 2 by k contingency table and analysed 
with Chi Square test for trend. Chi Square value (and degree of freedom) have been 
reported together with p value. Several groups have been compared on the basis of 
clinical and treatment variables (sex, age </>70yrs, time since diagnosis </>5yrs, T 
stage at timepoint of diagnosis (T1-T2 vs T3-T4), localisation (limbs vs other), 
number of treated lesions </>3, size of lesions </>3cm, presence of visceral 
metastases, treatment of pre-irradiated areas, presence of lymphoedema, complete 
treatment of deep margins, complete treatment of lateral margins, previous 
treatments (surgery, chemotherapy, radiotherapy, isolated limb perfusion (ILP), other 
treatments), number of ECT treatments (1 vs multiple), current (≤2 Ampère, >2 
Ampère), electrodes (hexagonal vs other)). Multivariable analysis was performed by 
logistic regression model using objective response (yes/no) and then complete 
response only (yes/no), using as covariates only significant variables observed in the 
univariable analysis. Local tumour control was expressed as local progression free 
survival which was the time from ECT up to the date to relapse or progression or last 
follow-up, (whichever came first). Overall survival was calculated from the first ECT 
up to death or last follow-up. Survival curves were calculated by the Kaplan–Meier 
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method. p < 0.05 was considered statistically significant. One-year survival and 95% 
confidence interval (C.I. 95%) were calculated using Kaplan-Meier survival analysis. 
Overall survival was calculated at death (for any reason) of patient or last follow-up, 
melanoma specific survival was calculated at death of patient for melanoma disease 
or last follow-up. Statistical analyses were performed with NCSS 9 software (NCSS, 
LLC. Kaysville, Utah, USA) 
 
Results 
Patients 
A total of 151 patients were treated by ECT and uploaded to the INSPECT database 
by 13 European centres (Bristol (n=4), Copenhagen (n=14), London (n=29), 
Manchester (n=10), Middlesbrough (n=14), Munich (n=19), Padova (n=7), Pavia 
(n=3), Prescot Merceyside (n=9), Rome (n=8), Turin (n=27), Warsaw (n=2), Wels 
(n=5)).  
Of these patients, 37 did not have a minimum follow-up time of 60 days (a requisite 
to evaluate the response to treatment by RECIST criteria). These patients were 
therefore excluded from the study (death not directly related to treatment (N=12; 8 of 
them died due to systemic disease progression, 4 of other causes unrelated to 
melanoma or ECT treatment), use of other treatments non-specified (N=6), systemic 
disease progression (N=6), inability to reach the hospital for follow-up visits (N=1), 
lost to follow-up (N=12)). 
Therefore, of 151 patients identified from the database, 114 patients have been 
evaluated for tumour response. Population and tumour characteristics of the entire 
cohort of 151 patients (506 treated lesions) and of the 114 patients (394 treated 
lesions) evaluable for response are reported in table 1. 
 
Anaesthesia 
Local or general anesthesia was selected according to the tumour burden and 
location as well as to patient’s choice, following the SOP (Standard Operating 
Procedures). General anaesthesia was used in the majority of cases (95 patients, 
63%). In 36 patients ECT was performed under local anesthesia and deep sedation 
(24%). The remaining 20 patients were treated with local anesthesia alone (13%). A 
similar percentage distribution was observed in the 114 patients group (62%, 26% 
and 12% respectively). 
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Electrochemotherapy 
123 patients received a single ECT session (82%), 21 patients (14%) were treated 
twice, 5 patients (3%) with three, 2 patients (1%) with 4 ECT sessions. Bleomycin 
was administered by systemic injection in 131 patients (87%) and by local injection in 
20 patients (13%). Electrodes used were: hexagonal in 383 (76%), row needle in 67 
(13%), plate in 20 (4%), multiple electrodes were used in 36 lesions (7%). Of the 506 
treated target lesions, 37 (7%) were previously irradiated. Deep margins were 
treated by ECT in 363 lesions (72%), lateral margins were reached in 385 lesions 
(76%). Similar percentage distributions were observed in the subgroup of 114 
patients and 394 target lesions evaluable for response (Table 1). 
 
Treatment toxicity 
No ECT-related serious adverse events were reported. Skin reaction (including 
hyperpigmentation and ulceration) after treatment was observed in 63 patients (42%) 
of which in 2 patients of grade G3. Fifteen patients experienced post-treatment 
complications: nausea (G1-G2) in 5 patients (3%), flu-like symptoms (G1-G2) in 6 
patients (4%), lymphoedema (G1-G2) in 4 patients (3%). A similar percentage 
distribution was observed in the 114 patients group (skin reaction 50% 2 of grade 
G3, nausea 4%, flu 5%, lymphoedema 4%). Post-treatment pain was observed in 59 
patients (39%), were mild in the majority of patients and could be managed with oral 
analgesics. No significant changes in pain and pain medication in the course of the 
treatment could be observed (Table 2). 
Locoregional tumour response 
394 target lesions could be evaluated for response at >60 days follow-up. Median 
size was 9 mm (I.Q. range 5-20 mm). At 60 days from ECT, 229 lesions showed a 
complete response (58%), 77 showed a partial response (19%) (Overall response 
306 of 394 lesions = 77 %), 79 lesions remained stable (20%), 6 had disease 
progression (2%) and 3 were not evaluable (1%) due to the presence of thick crusts. 
Of the 114 evaluable patients, at >60 days follow-up 55 had a complete response 
(48%), 29 a partial response (25%) (Overall response 80/114 patients – 73 %), 26 
patients were in stable disease (23%), 3 patients had disease progression (3%) and 
1 patient was not evaluable due to the presence of thick crusts. We found a 
significant trend between tumour size and complete response to ECT (p<0.0001, 
Table 3). 
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Predictive factors for response 
Among all clinical and technical covariates included in the univariate analysis, those 
significantly associated to response to treatment were: tumour size (<3 cm), absence 
of visceral metastases, treatment of non-irradiated areas, presence of 
lymphoedema, coverage of deep margins and lateral margins (Table 4).  
Looking at overall response (complete response + partial response = OR) in 
multivariate analysis, coverage of deep margins, absence of visceral metastases, 
presence of lymphoedema, treatment of non-irradiated areas were factors 
significantly influencing treatment efficacy. In multivariate analysis significant factors 
associated to a complete response to ECT treatment were: coverage of deep 
margins, previous irradiation of treated area, and tumour size (<3 cm) (Table 5). 
 
Local tumour control and survival 
Median follow-up time was 116 days [I.Q. range 66-201 days]. Local tumour control 
survival curve is shown in figure 1. Twenty-seven patients had been followed up for 
at least 200 days and at this time local tumour control survival rate was 86%.  
The 51 patients in complete response at 2 months of follow-up were locally disease 
free for a median time of 125 days [I.Q. range 70-209 days]. Eight of them had a 
second ECT for new lesions after a median time of 96 days [I.Q. range 61-154 days]. 
Five patients were treated for new lesions outside the treated area. Three patients 
were retreated for recurrences in the treated area, two of them had a total of 4 ECT 
sessions and maintained local tumour control for 374 and 447 days respectively.  
Overall, the 8 patients experienced median local tumour control survival of 254 days 
[I.Q. range 161-389 days]. 
 
Among the 29 patients with a partial response, 10 were re-treated by ECT after a 
median time period of 90 days [I.Q. range 58-131 days], and resulted in 2 complete 
responses, 4 partial responses, 1 stable disease, 1 progressive disease and 2 were 
not evaluable. For the 6 patients with CR/PR, local control of the disease was 
maintained for a median follow-up time of 125 days [I.Q. range 99-262 days].  
Overall 27 (23.7 %) patients were re-treated with ECT after a median follow-up time 
of 91 days [I.Q. range 61-133 days], and in these patients, local tumour control was 
maintained for a median time of 178 days since the first ECT session [I.Q. range 
106-277 days]. 
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One-year overall survival in this cohort of patients was 67% (C.I. 95%: 57%-77%), 
whilst melanoma specific survival was 74% (C.I. 95%: 64%-84%). 
 
Discussion 
The incidence of melanoma has been rising over a number of years and is currently 
the most common malignancy in young adults (American Cancer Society, 2015). 
Some of these patients will go on to develop metastases giving rise to pain, 
ulceration, malodor and bleeding. These patients have an immeasurable 
psychological burden and their quality of life can be adversely affected. The five-year 
survival for patients with in-transit disease has up to now ranged from 12-37% 33, 
although this will hopefully improve with novel treatment regimens 34,35. 
 
ECT is an established therapeutic approach for the local treatment of skin 
metastases regardless of tumour histology21,23. In a recent meta-analysis on more 
than 40 prospective studies comparing five skin-directed therapies (ECT, radiation, 
photodynamic therapy, intralesional therapy, and topical therapy), ECT demonstrated 
an OR rate of 75.4 % (CR rate, 47.5 %) with a low toxicity profile (grade 3 in less 
than 6 % of patients). In this analysis, melanoma comprised 83.3 % of all cutaneous 
metastases 31. Another previously published meta-analysis of ECT for cutaneous 
and/or subcutaneous malignancy (including primary nonmetastatic disease) reported 
a CR rate of 59% 8. 
 
Our data retrieved from this multicentre observational prospective study which 
included the largest cohort of patients treated by ECT reported, strongly confirm the 
results of previous studies, highlighting the clinical activity of ECT in terms of 
response rate and response duration 13,15-18,24-27,30,36. Indeed, at 2-month follow-up, a 
response was achieved in 77% of target lesions (58% CR rate) and in 73% of 
patients (48% achieving a CR). Notably, the local tumour control was 86% at 200 
days of follow-up, meaning that patients with CR maintained their response for a 
prolonged period of time.  
 
These results correspond to those reported by studies analysing long term follow–
up. Caracò et al. reported that 44.8% of complete responders experienced a long-
lasting response after one ECT session and were disease-free after a mean duration 
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of follow-up of 27.5 months 18. In our study as well as in former published studies, 
the clinical activity of ECT was accompanied with a favourable toxicity profile with no 
severe side effects. Concerns regarding post treatment pain have been addressed 
32,37
 with the majority of patients reported as experiencing no pain or mild pain. 
Patients deemed at a higher risk of post-procedure pain can be identified pre-
operatively, and cope well with an established pain management strategy. The 
results from this paper showed 39% of the patients suffered from post treatment 
pain, managed by oral analgesia alone. This is similar to that previously published 
32,37
. No other severe adverse effects were noted. 
 
Whilst the clinical indications and tolerability of ECT is widely accepted, a still 
controversial issue is the identification of patients most likely to develop and maintain 
response to ECT. This is particularly important since new and active systemic drugs 
for metastatic melanoma (both immune therapies such as anti-CTLA4 or anti-
PD1/PD1L inhibitors and anti-BRAF/MEK target inhibitors) are available that may 
also be used in the same population of patients. The aim of this study was to identify 
parameters significantly influencing treatment response and helping to decide 
whether a patient is more suitable for systemic therapy or ECT. To date, there is no 
consensus in the literature as to how best identify these factors. The only parameter 
which the large majority of publications agree on is the size of lesions 38. 
 
It is well known that smaller tumours respond better, likely both due to faster healing 
(time to clinical response), due to a more aggressive phenotype in larger tumours, 
and possibly also due to technical limitations when treating very large tumours 2,15,24. 
We found a significant and inverse trend between tumour size and treatment 
response. Treatment efficiency decreased with increasing size of tumour nodules 
(Table 3). 
However only a few studies have tried to identify other factors influencing treatment 
response. Solari et al. found that response rate significantly correlated at univariate 
analysis both with the number (< or >10) and the size (< or >2 cm) of metastases, 
whilst in multivariate analysis only the tumour size maintained a statistically 
significant correlation in 39 patients 27. However, this study was conducted on a 
relatively small cohort including not only melanoma but also other tumours. 
Campana et al. identified in their study on 85 metastatic melanoma patients tumour 
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size and number of lesions, as significant predictive factors for response in 
multivariate analysis 17. Increasing number of electrode applications and ECT cycles 
were reported as predictors of local tumour control and the location of nodules on the 
lower limb was associated with improved survival 17. 
 
In the present study, we identified the following predictors of response: coverage of 
deep tumour margins, absence of visceral metastases, presence of lymphoedema 
and treatment of non-irradiated areas. Our analysis identified factors not previously 
reported in melanoma patients. The size of the lesion, which is a well-known 
prognostic parameter in ECT treated patients (< 3 cm in diameter) was singled out 
by the multivariate model only in relation to a significantly higher probability of 
achieving a complete response to treatment. This factor was not associated with a 
better overall response. On the other hand, complete coverage of deep margins and 
treatment of tumours in non-irradiated areas were significant parameters on 
multivariate analysis on overall and complete response. The relevance of completely 
targeting the deep margins could imply that patients with deep and/or subcutaneous 
metastases could have a lower response rate to ECT in contrast to patients with 
superficial skin lesions, although the assessment of deep margins still needs to be 
assessed in a more reproducible way. 
 
The number of tumours was not found to be a predictor of locoregional tumour 
response in our patients. 
The biological background leading to a reduced ECT activity in the presence of these 
parameters can be hypothesized even if not specifically addressed in this paper. The 
presence of visceral metastases could be considered as a putative biomarker of 
rapid cell growth and therefore aggressive metastatic behaviour. In these cases, one 
could infer that the local approach by ECT alone would be inadequate to manage 
local disease occurrence or the onset of new skin lesions. In addition, there is a 
higher tumour load in patients with systemic metastases, and a retrograde 
metastasis from viscera to the skin is possible. This could occur if lymph node 
metastasis results in a blockage of lymph flow, incompetent lymphatic valves, and 
subsequent retrograde lymphatic flow. (Grinnell 1966) 
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Intriguingly, the presence of lymphoedema was associated with a higher response to 
ECT. Lymphoedema is a common surgical side effect of radical node dissection and 
therefore patients with skin “in-transit metastases” often present with this picture. 
Data is emerging that ECT may be an efficient way of presenting intact antigens to 
the immune system, as electroporation is essentially a non-thermal therapy 39. Case 
reports of excellent responses after sequential ECT and immunotherapy are 
accumulating, and a study has found homing of T-lymphocytes to tumour lesions 
after ECT of other lesions, in combination with local IL-2 34. What can be speculated, 
but must be further investigated, is that an increased presence of lymphocytes in the 
treated area may have a positive effect on response. Such a response may not be 
seen e.g. in isolated limb perfusion because the drugs used will also be cytotoxic to 
lymphocytes. 
 
Radiotherapy is not a standard treatment for primary melanoma, but can be used to 
treat metastatic lesions. The observation of better ECT response in non-irradiated 
lesions (when compared to lesions in patients with previous irradiation) could be 
explained by reduced clinical tumour activity due to the modification in the tumour 
microenvironment and vascularisation induced by radiotherapy. Fibrosis is a late 
side-effect of radiation caused by premature senescence and accelerated post-
mitotic differentiation, leading to excessive collagen production by irradiated 
mesenchymal cells (fibroblasts, myofibroblasts, and smooth muscle cells), and not 
by cell kill 40,41. The presence of fibrosis may alter the electric potential delivered 
during ECT treatment. Conversely there is laboratory evidence that ECT performed 
before radiotherapy 42 or in combination with irradiation 43, might give rise to good 
anti-tumour results. It is thought the anti-tumour effectiveness of ECT is increased by 
radiation in the laboratory model. Other studies have shown that ECT acts 
synergistically with radiotherapy, with enhanced tumour toxicity 42-44. Possibly, in 
melanoma, restricted blood flow and fibrosis may also lead to decreased 
immunological activity in the area. 
 
It is important to determine the various factors which will positively affect the 
outcome of melanoma patients treated with ECT. Our data suggest that patients with 
skin metastases, could be selected for ECT treatment if the disease was superficial, 
in the presence of lymphoedema, in the absence of visceral metastases or previous 
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irradiation, and if the tumour nodules were less than 3 cm dimension. It may even be 
possible that ECT could favourably influence immunotherapeutic approaches, and 
studies are ongoing to investigate this. Patients with visceral metastases, absence of 
lymphoedema, larger and deep skin metastases and with previous radiotherapy 
could be treated earlier with a systemic approach and ECT performed only if needed 
to control bleeding of metastases.  
 
There are a number of limitations to the current study. Patient review is not 
standardised in all the Centres involved in the data collection. In some units, ECT is 
carried out by specific personnel and therefore assessment of response is likely to 
be biased. The number of patients assessed for the cohort study does not accurately 
represent the total number of melanoma patients treated. The various centres joined 
InspECT at different times and the ability to upload data was related to local 
resources and the availability of personnel. The ability to determine whether or not 
the deep margin of a tumour is treated remains subjective, by the treating clinician. 
One way to objectively characterise the deep treatment margins would be 
intraoperative imaging by ultrasound. 
 
Future studies on ECT could explore the use of ECT as monotherapy for localised 
skin metastases, only adding systemic treatments when there is systemic 
progression to prevent early resistance to systemic treatments and to achieve long 
lasting survival rates. It is already well established, that ECT does not influence the 
metastatic potential of tumour cells 45. If it is not possible to treat deep tumour 
margins it may be necessary to add a systemic treatment early due to worse 
response rates (10.28 for CR and 28.45 for OR).  
ECT is a once-only treatment, and can be quickly performed, even before or 
between other treatments. Clear indications include bleeding 10,19, which is a 
frequent problem for patients afflicted with metastatic melanoma. Local responses, 
which are to a high degree achievable with ECT, may alleviate the patient from local 
tumour burden and progression. 
 
The collection of InspECT data began before the introduction of targeted therapies, 
like BRAF, ckit, MEK1 and NRAS mutations, and so this status has not been 
systematically evaluated in our patients. Future studies could ascertain whether ECT 
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activity could be influenced by the mutation status or are independent from it. 
Ultimately a randomised controlled trial will determine whether there is a difference in 
locoregional response rate and overall survival when ECT is compared to other well 
established treatment modalities. Future studies to explore the combination of ECT 
with systemic treatments will become necessary with time as more of our patients 
become eligible for treatment with new agents. 30. The combination of ECT with 
immunotherapy or targeted therapies could be a strategy to target both local and 
distant unreachable or untreated lesions 25.  
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TABLE 1 Patients characteristics 
 
 
Treated patients
(n=151)
Evaluable patients  
(n=114) 
Age (median [I.Q. range]) 75 65-82 76 70-82 
age 
151 
patients % 114 patients  % 
<50 11 7% 4 4% 
50-59 7 5% 3 3% 
60-69 29 19% 21 18% 
70-79 46 31% 40 35% 
80+ 58 38% 46 40% 
     
Years since diagnosis (median [I.Q. 
range]) 
2 1-5 2 1-4 
SEX (M:F) 59:92 39%:61% 42:72 37%:63%
   
TNM AT DIAGNOSIS 
  
T (T1,T2,T3,T4,Tx,Tis) 11,31,42,30,16,21 9,24,33,21,13,14 
N (N0,N1,N2,N3,Nx) 92,16,18,16,9 71,13,14,9,7 
M (M0,M1,Mx) 125,19,7 98,9,7 
PREVIOUS TREATMENTS 
   
Surgery 105 70% 76 67% 
Chemotherapy 44 29% 28 25% 
Radiotherapy 29 19% 17 15% 
Isolated limb perfusion 8 5% 7 6% 
Other 85 56% 60 53% 
# ECT PER PATIENT 
    
1 123 82% 87 76% 
2 21 14% 20 18% 
3 5 3% 5 4% 
4 2 1% 2 2% 
   
LESIONS
  
Total number of skin lesions 506 394 
Lesions per patient (median [I.Q. 
range]) 
3 1-6 3 1-6 
SIZE (median [I.Q. range]) 10 5-20 9 5-20 
< 5 mm 182 36% 144 36% 
6-10 mm 128 25% 109 28% 
11-20 mm 80 16% 58 15% 
21-30 mm 44 9% 32 8% 
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>30 mm 72 14% 51 13% 
LOCALISATION LARGEST 
NODULE
    
Head/Neck 15 10% 11 10% 
Trunk 24 16% 13 11% 
Limbs 104 69% 84 74% 
Multiple sites 8 5% 6 5% 
CURRENT PER NODULE 
    
< 1.5 A 73 15% 58 15% 
1.6-3 A 178 35% 140 35% 
3.1-5 A 127 25% 101 26% 
5.1-7 A 75 15% 59 15% 
7.1-10 A 41 8% 28 7% 
>10 A 12 2% 8 2% 
ELECTRODES 
    
Plate 20 4% 13 3% 
Row needle 67 13% 57 15% 
Hexagonal 383 76% 304 77% 
Multiple electrodes 36 7% 20 5% 
Preirradiated area (YES:NO) 37:469 7%:93% 19:375 5%:95%
Deep margins reached (YES:NO) 363:143 72%:28% 283:111 72%:28%
Lateral margins reached (YES:NO) 385:121 76%:24% 295:99 75%:25%
 
 
Table 2 Pain evaluation by Numeric Rating Scale (NRS) 
  
Before 
ECT 
Within
60 
days 
After 
60 
days 
P value 
Pain NRS         
Median NRS  0 1 1   
NRS range (min-max)  0-8 0-10 0-8   
          
Pain NRS categories         
0-2 Mild pain 77% 70% 68%   
3-5 Moderate pain 16% 19% 20%   
6-10 Severe pain 7% 11% 12%   
      P=0.5892 
  
      
  
Pain medication         
No pain 50% 41% 47%   
Pain sometimes, controlled by non-opioids 31% 24% 21%   
Pain controlled by non-opioids 15% 21% 25%   
Pain controlled by opioids 1% 4% 0%   
Uncontrolled pain 1% 4% 8%   
       P=0.0561 
 
Numeric Rating Scale (NRS) 
p values of Chi square for trend 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
TABLE 3. Response to ECT correlated to tumour size  
 
 SIZE < 5 mm % 6-10 mm % 11-20 mm % 21-30 mm % >30 mm %
CR 94 68% 70 64% 32 56% 11 34% 19 38%
NOT CR 45 32% 39 36% 25 44% 21 66% 31 62%
Chi square for trend = 20.385 (1 degree of freedom) P VALUE <0.0001 
           
OR 110 79% 86 79% 42 74% 25 78% 38 76%
NOT OR 29 21% 23 21% 15 26% 7 22% 12 24%
Chi square for trend = 0.3527 (1 degree of freedom) P VALUE = 0.5526
 
 
Complete response (CR) disappearance of the target lesion 
Overall response (OR) is CR + Partial response (PR) at least 30% decrease in the diameter of the target lesion 
 
 
 
TABLE 4. Significant factors associated with response to ECT related to nodules 
 
VARIABLES % CR ODDS RATIO 
(C.I.95%) 
P value 
Lesion size (mm) ≤ 30         62.9% 
>30          35.3% 
1.76 (1.34-2.32) 0.00005 
Visceral mts YES         30.0% 
NO           49.5% 
0.59 (0.45-0.77) 0.0001 
Lymphoedema YES         62.0% 
NO           61.7% 
1.01 (0.78-1.31) 0.9535 
Pre-irradiated area YES         31.6% 
NO           59.5% 
0.56 (0.34-0.92) 0.0219 
Deep margins treated YES         64.7% 
NO           41.4% 
1.61 (1.28-2.01) 0.00003 
Lateral margins treated YES         62.7% 
NO           44.4% 
1.45 (1.15-1.83) 0.0016 
    
 % OR ODDS RATIO 
(C.I. 95%) 
P value 
Lesion size (mm) ≤ 30         77.5% 
>30          76.5% 
1.02 (0.74-1.39) 0.9364 
Visceral mts YES         75.0% 
NO           72.5% 
1.11 (0.80-1.54) 0.5408 
Lymphoedema YES         96.2% 
NO           75.9% 
2.84 (1.56-5.14) 0.0006 
Pre-irradiated area YES         63.2% 
NO           78.4% 
1.48 (0.92-2.40) 0.1096 
Deep margins treated YES         85.2% 
NO           58.5% 
2.09 (1.62-2.69) <0.00001 
Lateral margins treated YES         83.0% 
NO           61.6% 
1.80 (1.40-2.33) 0.00001 
 
 
Complete response (CR) disappearance of the target lesion 
Overall response (OR) is CR + Partial response (PR) at least 30% decrease in the diameter of the target lesion 
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TABLE 5. LOGISTIC MULTIVARIATE ANALYSIS. Response to ECT related to nodules. 
 
 
 
LOGISTIC MULTIVARIATE ANALYSIS FOR COMPLETE RESPONSE 
 
COEFF. ST.ERR. ODDS RATIO (C.I. 
95%) 
P 
VALUE
LESION SIZE ≤ 3 CM 1.31 0.33 3.69 (1.95-6.98) <0.0001
ABSENCE OF VISCERAL 
METASTASES 
-0.08 0.37 0.92 (0.44-1.91) 0.829
PRESENCE OF LYMPHOEDEMA -0.37 0.30 0.69 (0.38-1.24) 0.215
NOT PREIRRADIATED AREA 1.17 0.58 3.24 (1.04-10.09) 0.043
DEEP MARGINS TREATED 2.40 0.69 10.98 (2.85-42.29) 0.0005
LATERAL MARGINS TREATED -1.01 0.70 0.36 (0.09-1.43) 0.147
LOGISTIC MULTIVARIATE ANALYSIS FOR OBJECTIVE RESPONSE  
 
COEFF. ST.ERR. ODDS RATIO (C.I. 
95%) 
P 
VALUE 
LESION SIZE ≤ 3 CM -0.50 0.48 0.61 (0.24-1.55) 0.296
ABSENCE OF VISCERAL 
METASTASES 
3.31 1.13 27.50 (3.01-251.21) 0.0033
PRESENCE OF LYMPHOEDEMA 1.45 0.64 4.28 (1.23-14.89) 0.022
NOT PREIRRADIATED AREA 1.58 0.73 4.28 (1.15-20.31) 0.032
DEEP MARGINS TREATED 3.35 0.73 28.45 (6.78-119.32) <0.0001
LATERAL MARGINS TREATED -1.37 0.72 0.25 (0.06-1.04) 0.056
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Figure 1. Local tumour control curve 
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